Janus kinase inhibitors in localized scleroderma: a systematic literature review
Turkish Journal of Medical Sciences · 20.06.2025 · 55 (3) · 533-539
DOI: 10.55730/1300-0144.6000 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Turkish Journal of Medical Sciences, online erschienen am 20.06.2025. Verfasst von Seher Şener und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric Rheumatology, Department of Pediatrics, Adana City Training and Research Hospital, Adana, Turkiye. Hauptthemen laut MEDLINE: Janus Kinase Inhibitors, Scleroderma, Localized. Die Arbeit wurde bisher 5-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/aim: Reports on the use of Janus kinase (JAK) inhibitors in the treatment of localized scleroderma are increasing in the literature. In this review, we examined the published studies regarding the use of JAK inhibitors in patients with localized scleroderma. Materials and methods: We searched MEDLINE and Scopus for articles on patients with localized scleroderma treated with JAK inhibitors. The search included articles from the inception of these databases through August 1st, 2024.
Results
Our literature search showed 11 articles describing 17 patients with localized scleroderma treated with JAK inhibitors. Generalized morphea (47.1%) was the most common type of localized scleroderma in patients treated with JAK inhibitors. The most frequently used JAK inhibitor was tofacitinib (64.7%). In some cases, baricitinib (17.6%) and ruxolitinib (17.6%) were also preferred. All JAK inhibitors were mainly preferred for the treatment of resistant/progressive skin disease in these patients (60.7%). The improvement rate associated with JAK inhibitors was 88.2%. Relapse occurred in 33.3% of patients treated with JAK inhibitors. Side effects were reported in 18.2% of patients: one patient was diagnosed to have diffuse large B-cell lymphoma (n=1) while on tofacitinib.
Conclusion
JAK inhibitors could be considered as a therapeutic option, especially in patients with refractory localized scleroderma, but more extensive clinical trials are needed to clarify questions regarding their efficacy and safety data.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Pediatric Rheumatology, Department of Pediatrics, Adana City Training and Research Hospital, Adana, Turkiye.
- Department of Cardiology, Erasmus University Medical Center, Rotterdam, Netherlands.
- Division of Pediatric Rheumatology, Department of Pediatrics, Faculty of Medicine, Hacettepe University, Ankara, Turkiye.
- Division of Rheumatology, Department of Internal Medicine, Ankara Etlik State Research and Training Hospital, Ankara, Turkiye.
- Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Hacettepe University, Ankara, Turkiye.
ORCID-Profile: Seher Şener, Yusuf Ziya Şener, Ezgi Deniz Batu, Alper Sari, Ali Akdoğan
Zitieren
APA
Şener, S., Şener, Y. Z., Batu, E. D., Sari, A., & Akdoğan, A. (2025). Janus kinase inhibitors in localized scleroderma: a systematic literature review. Turkish Journal of Medical Sciences, 55(3), 533-539. https://doi.org/10.55730/1300-0144.6000
Vancouver
Şener S, Şener YZ, Batu ED, Sari A, Akdoğan A. Janus kinase inhibitors in localized scleroderma: a systematic literature review. Turkish Journal of Medical Sciences. 2025;55(3):533-539. doi:10.55730/1300-0144.6000
BibTeX
@article{ener2025,
author = {Şener, Seher and Şener, Yusuf Ziya and Batu, Ezgi Deniz and Sari, Alper and Akdoğan, Ali},
title = {Janus kinase inhibitors in localized scleroderma: a systematic literature review},
journal = {Turkish Journal of Medical Sciences},
year = {2025},
volume = {55},
number = {3},
pages = {533--539},
doi = {10.55730/1300-0144.6000}
}
EUVIMED